SAB Biotherapeutics, Inc. SABS

3.29 (0.06) (1.79%) as of 25 Sep
Market cap
$304.8M
P/E
0.0×
Dec '17 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— 0.00 0.00 0.00 0.00 0.00 —
P/S ratio
— 0.00 3.51 1.18 17.26 21.57 —
P/FCF ratio
— 0.00 0.00 0.00 0.00 0.00 —
P/Operating CF
— (150,140.83) (43.77) (18.19) (2.87) (3.68) —
P/B ratio
— 93,838.02 5.54 0.91 0.67 1.35 —
EV/Sales
— 0.00 2.92 0.73 (6.47) 10.83 —
EV/EBITDA
— 0.00 0.00 0.00 0.42 0.00 —
EV/FCF
— 0.00 (19.84) (0.68) 0.57 (0.51) —
Current Ratio
— 3.11 1.90 1.47 5.45 2.98 9.46
Net Debt/EBITDA
— (0.40) 3.05 0.42 1.55 0.46 2.03
Debt/Equity
— 0.11 0.10 0.13 0.06 0.13 0.02
ROE
— 51.88% (44.21%) (53.85%) (95.51%) (81.92%) 4.80%
ROA
— 71.17% (24.91%) (28.39%) (62.58%) (53.23%) 3.93%
ROIC
— 42.13% (302.49%) (89.55%) (573.17%) (316.08%) (52.73%)
Return on Tangible Assets
— 52.61% (35.68%) (61.74%) (62.21%) (109.38%) 4.11%
Average Days of Receivables
— 135.92 48.03 84.85 0.00 15.18 0.00
Earnings Yield
— 0.00% (8.03%) (65.84%) (110.63%) (97.10%) —
Free Cash Flow Yield
— 0.00% (4.19%) (90.31%) (65.39%) (98.65%) —
Free Cash Flow per Share
— (1.07) (3.28) (5.87) (4.58) (3.74) (2.37)
Book value per Share
— 15.36 14.10 7.14 10.38 2.80 7.84
Free Cash Flow
— (2.72) (8.96) (25.55) (25.27) (34.63) (45.71)
EV/EBIT
— 0.00 0.00 0.00 0.38 0.00 —
Other line items

Show all line items

Columns are period end dates